Amgen, Inc.

Climb Bio, Inc. appoints Douglas E. Williams, Ph.D., as Chair of its Board of Directors, succeeding Andrew Levin, who remains a director. Williams brings over 30 years of biotech leadership experience, including roles at Sana Biotechnology, Codiak BioSciences, and Biogen. He will guide Climb Bio's mission to develop treatments for immune-mediated diseases, focusing on the company's lead product, budoprutug.

AstraZeneca and Amgen's TEZSPIRE showed significant reduction in nasal polyps and congestion in Phase III WAYPOINT trial for chronic rhinosinusitis with nasal polyps (CRSwNP), offering a potential new treatment option for patients.

AstraZeneca and Amgen report positive phase 3 WAYPOINT trial results for Tezspire in chronic rhinosinusitis with nasal polyps, showing significant reduction in nasal polyps and congestion. Tezspire, targeting TSLP, offers a potential new treatment option for patients.

The global biotechnology market is projected to reach $550.83 billion in 2024 and $2667.36 billion by 2034, driven by advancements in synthetic biology, CRISPR, and genomic sequencing. North America is expected to lead, with a revenue of $231.68 billion in 2024, due to established agricultural biotechnology and a robust GMO framework. Key players include Johnson & Johnson, Roche, Pfizer, and Novartis.

AstraZeneca and Amgen's Tezspire met primary endpoint in Phase III WAYPOINT study, showing significant efficacy in chronic rhinosinusitis with nasal polyps. Tezspire reduced nasal polyps size and congestion with a consistent safety profile. Analysts note potential regulatory risks due to single study evaluation, contrasting with Sanofi and Regeneron's Dupixent, which had two pivotal studies. AstraZeneca and Amgen plan to share data with regulatory authorities and present at a medical congress.

Imugene has dosed the first patient with its onCARlytics intratumoural combination trial for colorectal cancer at Northwestern University. The Phase-1 OASIS trial combines CD19 oncolytic virotherapy with blinatumomab to assess safety and tolerability. This approach aims to render 'invisible' solid cancers visible and vulnerable to CD19 therapies, potentially extending treatment options for advanced solid tumours.

Roflumilast cream 0.15% showed high efficacy in treating mild to moderate atopic dermatitis in patients aged 6 years and older, with more patients achieving a validated IGA-AD score of 0/1 and minimal application site irritation.